Dendreon Announces Sale of New Jersey Plant to Novartis for $43M in Cash

Dendreon Corporation (NASDAQ: DNDN ) today announced the sale of its immunotherapy manufacturing facility (IMF) based in Morris Plains, New Jersey, to Novartis Pharmaceuticals Corporation (NYSE: NVS ) for $43 million in cash. Dendreon's Morris Plains, New Jersey, facility is a 173,100 square foot state-of-the-art IMF, featuring revolutionary capabilities to manufacture PROVENGE® (sipuleucel-T),